α-Hydroxytriazolam-d4 solution

Description

• General description: a-Hydroxytriazolam is a major urinary and blood metabolite of the benzodiazepine, triazolam, a pharmaceutical used to treat severe insomnia. This stable-labeled internal standard is suitable for triazolam testing or isotope dilution methods by GC/MS or LC/MS for clinical toxicology, urine drug testing, pain prescription monitoring or forensic analysis.
• Application: Pharmacokinetic Analysis of α-Hydroxytriazolam: A study focused on the urinary excretion of α-Hydroxytriazolam following a single dose of Halcion. This research provides critical insights into the metabolism of benzodiazepines, emphasizing the role of α-Hydroxytriazolam-d₄ as a stable isotope-labeled standard in tracing metabolic pathways in clinical pharmacology (Lin et al., 2005).Forensic Toxicology and Metabolite Confirmation: Another significant study utilized GC-MS to confirm the presence of urinary benzodiazepine metabolites, including α-Hydroxytriazolam. This research underscores the utility of α-Hydroxytriazolam-d₄ in forensic analysis, aiding in the detection and confirmation of benzodiazepine use and abuse in legal and medical settings (Meatherall, 1994).
• Legal Information: CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany